Literature DB >> 12867233

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Arnfried U Klingbeil1, Markus Schneider, Peter Martus, Franz H Messerli, Roland E Schmieder.   

Abstract

PURPOSE: Antihypertensive medications have different effects on left ventricular mass. We conducted a meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass.
METHODS: Medical databases and review articles were screened for double-blind, randomized controlled trials (through September 2002) that reported the effects of diuretics, beta-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin II receptor antagonists on echocardiographic left ventricular mass in essential hypertension. Treatment arms of the same drug class, weighted for the number of patients, were combined. Analysis of covariance was performed to detect differences among drug classes in effects on left ventricular structure.
RESULTS: Eighty trials with 146 active treatment arms (n = 3767 patients) and 17 placebo arms (n = 346 patients) were identified. Adjusted for treatment duration and change in diastolic blood pressure, there was a significant difference (P = 0.004) among medication classes: left ventricular mass index decreased by 13% with angiotensin II receptor antagonists (95% confidence interval [CI]: 8% to 18%), by 11% with calcium antagonists (95% CI: 9% to 13%), by 10% with ACE inhibitors (95% CI: 8% to 12%), by 8% with diuretics (95% CI: 5% to 10%), and by 6% with beta-blockers (95% CI: 3% to 8%). In pairwise comparisons, angiotensin II receptor antagonists, calcium antagonists, and ACE inhibitors were more effective at reducing left ventricular mass than were beta-blockers (all P <0.05 with Bonferroni correction).
CONCLUSIONS: Antihypertensive drug classes have different effects on left ventricular mass reduction. Whether a greater reduction of left ventricular mass results in better clinical outcomes remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867233     DOI: 10.1016/s0002-9343(03)00158-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  143 in total

Review 1.  Bringing prevention in geriatrics: evidences from cardiovascular medicine supporting the new challenge.

Authors:  Angelo Scuteri; Edward G Lakatta
Journal:  Exp Gerontol       Date:  2012-03-03       Impact factor: 4.032

2.  Mineralocorticoid-receptor blockade in hypertensive patients during angiotensin-converting enzyme inhibition: effects on left ventricular mass.

Authors:  Robert M Carey; Alexander G Logan
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 3.  Pharmacogenetics of antihypertensive drug response.

Authors:  Reinhold Kreutz
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

4.  Cardiovascular disease: Stenting in renovascular disease--good news for the heart?

Authors:  Lars Christian Rump; Lorenz Sellin
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

Review 5.  Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index.

Authors:  Charlotte H Manisty; Alun D Hughes
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 6.  Echocardiographic quantification of left ventricular mass: prognostic implications.

Authors:  Rajiv S Swamy; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

Review 7.  Applied Healthspan engineering.

Authors:  James W Larrick; Andrew Mendelsohn
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

8.  Heart failure and cardiac hypertrophy.

Authors:  J Eduardo Rame; Daniel L Dries
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 9.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 10.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.